UPCOMING WEBINARS

October 23, 2012 Clinical and Business Rewards of Using Laser in PracticeTo register https://www2.gotomeeting.com/register/793806762

November 27, 2012 Current Research in Low Level Laser Therapy

To register https://www2.gotomeeting.com/register/415407642

UPCOMING SEMINARS

Theralase’s Dr. Rhonda Mostyn will be presenting “Modern Science, Classic Healing: Therapeutic Laser Therapy and Chiropractic” at Parker Seminars Toronto on Friday, September 21, 2012 at 11:00 am.

CORPORATE UPDATESTheralase Creates Two Operating Divisions

On August 16, 2012, Theralase announced that it is reorganizing its operations into two separate reportable operating divisions to better service and focus the company's resources for both independent markets. The Therapeutic Laser Technology (TLT) division will be responsible for all aspects of the Company's burgeoning therapeutic laser business, which manufactures products used by healthcare practitioners predominantly for the healing of pain and the Photo Dynamic Therapy (PDT) division, which researches and develops Photo Dynamic Compounds (PDCs) for the destruction of primarily cancer.

It has become evident through the recent successes of both technology platforms that these two operating divisions have unique requirements in terms of financing, staffing, logistics and resource allocation. Our intent is to manage and focus the direction of each division to better execute on their respective strategic objectives. Theralase's mandate is to build both the TLT and PDT divisions into separate $50 million annual recurring revenue models within the next 5 to 7 years.

Photo Dynamic Therapy PDT division

There exists a substantial stream of research on the amount of systemic cytotoxic drugs and physical modalities associated with different types of radiation therapy. Despite its many successes, and in spite of decades of advanced research with highly sophisticated instrumentation, it has not solved many of the basic mysteries of cancer. Worse yet, every gain seems to be more than offset by additional serious problems and contradictions.

Theralase Inc., therefore, offers an innovative Photodynamic therapy (PDT) paradigm and patented approach for the novel anti-cancer technology platform.

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments.

However, contemporary PDT produces mostly superficial effects. Due to a limited light penetration through tissues, the depth of tumor destruction ranges from a few millimeters to up to 1 centimeter. Theralase’s breaking-ground technology offers a complete illumination of this apparent disadvantage. Therefore, Theralase’s technology platform, which offers a number of significant technological improvements and a barrier-breaking innovation, has the potential to become the first PDT integrated into the mainstream of cancer treatment.

Theralase Identifies the First Cancer Target for its Advanced Photo Dynamic Therapy

On July 18, 2012, Theralase announced that it has selected bladder cancer as the first clinical target in its Novel Photo Dynamic Compound (PDC) research. Theralase now has a clear direction with which to proceed with FDA Clinical Trials. Bladder cancer is the fifth most common cancer in North America being the fourth most common in men and the eighth most common in woman. In North America, it is estimated that there will be over 77,000 new cases and over 15,000 deaths annually.

The Theralase light activated PDC drug has been proven to be superior to any currently approved FDA PDC drug on the market, tested in Theralase’s lab and we are working hard to help eliminate this devastating disease that can dramatically affect so many families.

Q3 - September 2012

THERALASE QUARTERLY NEWSLETTER An update for clients, investors and employees

Theralase plans to aggressively pursue commercialization of our ground-breaking PDC technology through the accelerated FDA regulatory approval process. Theralase feels its technology will prove as effective in bladder cancer preclinical trials that will eventually lead to FDA clinical approval.

Theralase Accelerates Intellectual Property Strategy

On April 13, 2012, Theralase Technologies Inc. announced that it has filed a patent application for a newly developed Photo Dynamic Compound (PDC) to be added to its library of patented Photo Dynamic Compounds. It has been a stated objective to build on these important existing holdings and continue to expand the Intellectual Property footprint of the corporation. This filing represents a significant step in this regard and will specifically target new avenues in the destruction of cancers, bacteria and viruses.

"I had indicated to our shareholders that we would quickly show evidence of our IP strategy," said Roger Dumoulin-White, CEO of Theralase Technologies. "We firmly believe that our patents will be invaluable to Theralase as we continue to execute on our growth plan on the road to commercialization.”

Mr. White added, “Further to our press release of March 28, 2012, I am pleased to say that the mice, with under the skin colon cancer tumours treated with Theralase’s patented anti-cancer PDC technologies have survived and flourished forty-eight days post treatment; the mice continue to be cancer free. Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future.”

Theralase Identifies Leading Anti-Cancer Drug Candidate

On March 14, 2012, Theralase Technologies Inc. announced that it is pursuing FDA Phase 1 approval for its patented Photo Dynamic Compounds (PDCs).

Theralase has successfully identified the leading drug candidate, which will be used for safety and efficacy clinical testing in human cancer patients. In multiple preclinical studies, the leading drug candidate has been selected from Theralase’s library of PDCs and has repeatedly demonstrated:

• extremely high efficacy, virtually 100% kill rate, in various cancer cell lines including brain and colorectal cancers• robust destruction of subcutaneous (under the skin) cancerous tumours in animals• extremely low toxicity • high stability, allowing for a long shelf life

The preclinical results were reviewed by SPIE (The International Society for Optics and Photonics) and were accepted by the Conference Chairs for presentation at the SPIE Photonics Europe conference in Brussels, Belgium.Theralase will validate its extensive data with additional cancer animal models and toxicology analyses. This will provide the results required by the FDA to design a FDA Phase 1 clinical human study to commence in 2013 with scheduled completion in 2014. Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "Achievement of this critical milestone represents irrefutable proof that the Theralase leading drug PDC candidate is effective in the destruction of cancer in live animal models. The treatment was well tolerated by the animals, eliminating their cancer without any adverse effects. The Theralase leading drug candidate has been proven to be superior to any currently approved FDA PDC drug on the market, tested in our lab.”

Theralase Featured on "The Next Biggest Winner" Business TV Series

Theralase was featured on "The Next Biggest Winner", a television series devoted to discovering undervalued companies with the ability to grow significantly in shareholder value and become a big winner as an investment opportunity.

The TV show, "The Next Biggest Winner," which showcases companies with significant growth potential scheduled an in-depth interview with Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. on the iChannel, Tuesday, August 14th at 7:30pm. The iChannel has over 1.3 million affluent Canadian subscribers who look to its business programming for new investment opportunities.

To view the interview, please visit http://www.thenextbiggestwinner.com/theralase-technologies-inc/

Therapeutic Laser Technology (TLT) division

Low Level Laser Therapy (LLLT) is the drug-free, non-invasive and safe (FDA recognised) clinical application of light in the range of 1mW – 500mW to a patient to promote tissue regeneration, reduce inflammation and relieve pain. Theralase technology is the only product on the market that activates all three known cellular pathways (ATP production, iNOS production and Na+ / K+ pump regulation) and provides a depth of penetration of four inches into tissue. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. The White Paper “UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)” may be accessed from the Theralase website and offers independent clinical studies to support the science.

Theralase Establishes Middle East Distribution Network

On May 30, 2012, Theralase Technologies Inc. announced that it had entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria.

MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts including numerous major hospitals, medical clinics and doctors in the region. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.

Theralase Presents at BioFinance 2012 Life Sciences Conference

Roger Dumoulin-White, President and CEO presented the latest corporate information at the BioFinance 2012 conference held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada, which highlights more than 60 diverse life science companies, and the investment opportunities that they present. BioFinance 2012 also featured 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation took place Wednesday, May 30th at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase presented on the strategic direction and recent accomplishments of the company followed by a short Q&A period and one-on-one meetings with investors.

Theralase Closes Equity Financing

On April 13, 2012 Theralase Technologies Inc. stated that it has closed a previously announced private placement (the "Private Placement") of 3,000,000 units (the "Units") at a price of Cdn $0.25 per Unit for gross proceeds of CDN $750,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non-transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the purchaser to purchase one additional common share (a "Warrant Share") in the capital of the Company until April 13, 2013 at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month hold period, expiring August 13, 2012.

The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company's prospects in a number of areas; specifically:

• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network• Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of bacteria and viruses • TLC-1000 and TLC-900 therapeutic medical laser USA sales and marketing expansion• TLC-1000 therapeutic medical laser incorporating TENS (Transcutaneous Electrical Nerve Stimulation)• TLC-2000 therapeutic medical biofeedback laser commercialization

OUTLOOK

Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the TLC-900 controllerless laser series in the Canadian, US and international markets in 2012, supported by new independent scientific research confirming the effectiveness of Theralase’s proprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedback technology for launch in the first quarter of 2013, while researching and developing its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.

The groundwork has been laid for significant growth. Our proven patented technology has no equal and our ability to dramatically scale sales and marketing geographically as well as demographically will allow Theralase significant first mover market advantage. Theralase is currently debt free as it utilizes its profits from the sale of its TLC-1000 and TLC-900 Therapeutic Medical Laser platforms to pay for its future growth in the form of the launch of the TLC-2000 Biofeedback Therapeutic Laser Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer Destruction Technology.

This newsletter contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

For more information, please contact:

Roger Dumoulin-White President & CEO, 416-447-8455 ext. 225 rwhite@theralase.com

Greg BewshDirector of Investor Relations,416-447-8455 ext. 262gbewsh@theralase.com

Kristina HacheyChief Financial Officer

416-447-8455 ext. 224khachey@theralase.com

Dr. Arkady MandelChief Scientific Officer

416-447-8455 ext. 242amandel@theralase.com

UPCOMING WEBINARS

October 23, 2012 Clinical and Business Rewards of Using Laser in PracticeTo register https://www2.gotomeeting.com/register/793806762

November 27, 2012 Current Research in Low Level Laser Therapy

To register https://www2.gotomeeting.com/register/415407642

UPCOMING SEMINARS

Theralase’s Dr. Rhonda Mostyn will be presenting “Modern Science, Classic Healing: Therapeutic Laser Therapy and Chiropractic” at Parker Seminars Toronto on Friday, September 21, 2012 at 11:00 am.

CORPORATE UPDATESTheralase Creates Two Operating Divisions

On August 16, 2012, Theralase announced that it is reorganizing its operations into two separate reportable operating divisions to better service and focus the company's resources for both independent markets. The Therapeutic Laser Technology (TLT) division will be responsible for all aspects of the Company's burgeoning therapeutic laser business, which manufactures products used by healthcare practitioners predominantly for the healing of pain and the Photo Dynamic Therapy (PDT) division, which researches and develops Photo Dynamic Compounds (PDCs) for the destruction of primarily cancer.

It has become evident through the recent successes of both technology platforms that these two operating divisions have unique requirements in terms of financing, staffing, logistics and resource allocation. Our intent is to manage and focus the direction of each division to better execute on their respective strategic objectives. Theralase's mandate is to build both the TLT and PDT divisions into separate $50 million annual recurring revenue models within the next 5 to 7 years.

Photo Dynamic Therapy PDT division

There exists a substantial stream of research on the amount of systemic cytotoxic drugs and physical modalities associated with different types of radiation therapy. Despite its many successes, and in spite of decades of advanced research with highly sophisticated instrumentation, it has not solved many of the basic mysteries of cancer. Worse yet, every gain seems to be more than offset by additional serious problems and contradictions.

Theralase Inc., therefore, offers an innovative Photodynamic therapy (PDT) paradigm and patented approach for the novel anti-cancer technology platform.

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments.

However, contemporary PDT produces mostly superficial effects. Due to a limited light penetration through tissues, the depth of tumor destruction ranges from a few millimeters to up to 1 centimeter. Theralase’s breaking-ground technology offers a complete illumination of this apparent disadvantage. Therefore, Theralase’s technology platform, which offers a number of significant technological improvements and a barrier-breaking innovation, has the potential to become the first PDT integrated into the mainstream of cancer treatment.

Theralase Identifies the First Cancer Target for its Advanced Photo Dynamic Therapy

On July 18, 2012, Theralase announced that it has selected bladder cancer as the first clinical target in its Novel Photo Dynamic Compound (PDC) research. Theralase now has a clear direction with which to proceed with FDA Clinical Trials. Bladder cancer is the fifth most common cancer in North America being the fourth most common in men and the eighth most common in woman. In North America, it is estimated that there will be over 77,000 new cases and over 15,000 deaths annually.

The Theralase light activated PDC drug has been proven to be superior to any currently approved FDA PDC drug on the market, tested in Theralase’s lab and we are working hard to help eliminate this devastating disease that can dramatically affect so many families.

Theralase plans to aggressively pursue commercialization of our ground-breaking PDC technology through the accelerated FDA regulatory approval process. Theralase feels its technology will prove as effective in bladder cancer preclinical trials that will eventually lead to FDA clinical approval.

Theralase Accelerates Intellectual Property Strategy

On April 13, 2012, Theralase Technologies Inc. announced that it has filed a patent application for a newly developed Photo Dynamic Compound (PDC) to be added to its library of patented Photo Dynamic Compounds. It has been a stated objective to build on these important existing holdings and continue to expand the Intellectual Property footprint of the corporation. This filing represents a significant step in this regard and will specifically target new avenues in the destruction of cancers, bacteria and viruses.

"I had indicated to our shareholders that we would quickly show evidence of our IP strategy," said Roger Dumoulin-White, CEO of Theralase Technologies. "We firmly believe that our patents will be invaluable to Theralase as we continue to execute on our growth plan on the road to commercialization.”

Mr. White added, “Further to our press release of March 28, 2012, I am pleased to say that the mice, with under the skin colon cancer tumours treated with Theralase’s patented anti-cancer PDC technologies have survived and flourished forty-eight days post treatment; the mice continue to be cancer free. Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future.”

Theralase Identifies Leading Anti-Cancer Drug Candidate

On March 14, 2012, Theralase Technologies Inc. announced that it is pursuing FDA Phase 1 approval for its patented Photo Dynamic Compounds (PDCs).

Theralase has successfully identified the leading drug candidate, which will be used for safety and efficacy clinical testing in human cancer patients. In multiple preclinical studies, the leading drug candidate has been selected from Theralase’s library of PDCs and has repeatedly demonstrated:

• extremely high efficacy, virtually 100% kill rate, in various cancer cell lines including brain and colorectal cancers• robust destruction of subcutaneous (under the skin) cancerous tumours in animals• extremely low toxicity • high stability, allowing for a long shelf life

The preclinical results were reviewed by SPIE (The International Society for Optics and Photonics) and were accepted by the Conference Chairs for presentation at the SPIE Photonics Europe conference in Brussels, Belgium.Theralase will validate its extensive data with additional cancer animal models and toxicology analyses. This will provide the results required by the FDA to design a FDA Phase 1 clinical human study to commence in 2013 with scheduled completion in 2014. Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "Achievement of this critical milestone represents irrefutable proof that the Theralase leading drug PDC candidate is effective in the destruction of cancer in live animal models. The treatment was well tolerated by the animals, eliminating their cancer without any adverse effects. The Theralase leading drug candidate has been proven to be superior to any currently approved FDA PDC drug on the market, tested in our lab.”

Theralase Featured on "The Next Biggest Winner" Business TV Series

Theralase was featured on "The Next Biggest Winner", a television series devoted to discovering undervalued companies with the ability to grow significantly in shareholder value and become a big winner as an investment opportunity.

The TV show, "The Next Biggest Winner," which showcases companies with significant growth potential scheduled an in-depth interview with Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. on the iChannel, Tuesday, August 14th at 7:30pm. The iChannel has over 1.3 million affluent Canadian subscribers who look to its business programming for new investment opportunities.

To view the interview, please visit http://www.thenextbiggestwinner.com/theralase-technologies-inc/

Therapeutic Laser Technology (TLT) division

Low Level Laser Therapy (LLLT) is the drug-free, non-invasive and safe (FDA recognised) clinical application of light in the range of 1mW – 500mW to a patient to promote tissue regeneration, reduce inflammation and relieve pain. Theralase technology is the only product on the market that activates all three known cellular pathways (ATP production, iNOS production and Na+ / K+ pump regulation) and provides a depth of penetration of four inches into tissue. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. The White Paper “UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)” may be accessed from the Theralase website and offers independent clinical studies to support the science.

Theralase Establishes Middle East Distribution Network

On May 30, 2012, Theralase Technologies Inc. announced that it had entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria.

MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts including numerous major hospitals, medical clinics and doctors in the region. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.

Theralase Presents at BioFinance 2012 Life Sciences Conference

Roger Dumoulin-White, President and CEO presented the latest corporate information at the BioFinance 2012 conference held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada, which highlights more than 60 diverse life science companies, and the investment opportunities that they present. BioFinance 2012 also featured 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation took place Wednesday, May 30th at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase presented on the strategic direction and recent accomplishments of the company followed by a short Q&A period and one-on-one meetings with investors.

Theralase Closes Equity Financing

On April 13, 2012 Theralase Technologies Inc. stated that it has closed a previously announced private placement (the "Private Placement") of 3,000,000 units (the "Units") at a price of Cdn $0.25 per Unit for gross proceeds of CDN $750,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non-transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the purchaser to purchase one additional common share (a "Warrant Share") in the capital of the Company until April 13, 2013 at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month hold period, expiring August 13, 2012.

The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company's prospects in a number of areas; specifically:

• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network• Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of bacteria and viruses • TLC-1000 and TLC-900 therapeutic medical laser USA sales and marketing expansion• TLC-1000 therapeutic medical laser incorporating TENS (Transcutaneous Electrical Nerve Stimulation)• TLC-2000 therapeutic medical biofeedback laser commercialization

OUTLOOK

Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the TLC-900 controllerless laser series in the Canadian, US and international markets in 2012, supported by new independent scientific research confirming the effectiveness of Theralase’s proprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedback technology for launch in the first quarter of 2013, while researching and developing its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.

The groundwork has been laid for significant growth. Our proven patented technology has no equal and our ability to dramatically scale sales and marketing geographically as well as demographically will allow Theralase significant first mover market advantage. Theralase is currently debt free as it utilizes its profits from the sale of its TLC-1000 and TLC-900 Therapeutic Medical Laser platforms to pay for its future growth in the form of the launch of the TLC-2000 Biofeedback Therapeutic Laser Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer Destruction Technology.

This newsletter contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

For more information, please contact:

Roger Dumoulin-White President & CEO, 416-447-8455 ext. 225 rwhite@theralase.com

Greg BewshDirector of Investor Relations,416-447-8455 ext. 262gbewsh@theralase.com

Kristina HacheyChief Financial Officer

416-447-8455 ext. 224khachey@theralase.com

Dr. Arkady MandelChief Scientific Officer

416-447-8455 ext. 242amandel@theralase.com

UPCOMING WEBINARS

October 23, 2012 Clinical and Business Rewards of Using Laser in PracticeTo register https://www2.gotomeeting.com/register/793806762

November 27, 2012 Current Research in Low Level Laser Therapy

To register https://www2.gotomeeting.com/register/415407642

UPCOMING SEMINARS

Theralase’s Dr. Rhonda Mostyn will be presenting “Modern Science, Classic Healing: Therapeutic Laser Therapy and Chiropractic” at Parker Seminars Toronto on Friday, September 21, 2012 at 11:00 am.

CORPORATE UPDATESTheralase Creates Two Operating Divisions

On August 16, 2012, Theralase announced that it is reorganizing its operations into two separate reportable operating divisions to better service and focus the company's resources for both independent markets. The Therapeutic Laser Technology (TLT) division will be responsible for all aspects of the Company's burgeoning therapeutic laser business, which manufactures products used by healthcare practitioners predominantly for the healing of pain and the Photo Dynamic Therapy (PDT) division, which researches and develops Photo Dynamic Compounds (PDCs) for the destruction of primarily cancer.

It has become evident through the recent successes of both technology platforms that these two operating divisions have unique requirements in terms of financing, staffing, logistics and resource allocation. Our intent is to manage and focus the direction of each division to better execute on their respective strategic objectives. Theralase's mandate is to build both the TLT and PDT divisions into separate $50 million annual recurring revenue models within the next 5 to 7 years.

Photo Dynamic Therapy PDT division

There exists a substantial stream of research on the amount of systemic cytotoxic drugs and physical modalities associated with different types of radiation therapy. Despite its many successes, and in spite of decades of advanced research with highly sophisticated instrumentation, it has not solved many of the basic mysteries of cancer. Worse yet, every gain seems to be more than offset by additional serious problems and contradictions.

Theralase Inc., therefore, offers an innovative Photodynamic therapy (PDT) paradigm and patented approach for the novel anti-cancer technology platform.

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments.

However, contemporary PDT produces mostly superficial effects. Due to a limited light penetration through tissues, the depth of tumor destruction ranges from a few millimeters to up to 1 centimeter. Theralase’s breaking-ground technology offers a complete illumination of this apparent disadvantage. Therefore, Theralase’s technology platform, which offers a number of significant technological improvements and a barrier-breaking innovation, has the potential to become the first PDT integrated into the mainstream of cancer treatment.

Theralase Identifies the First Cancer Target for its Advanced Photo Dynamic Therapy

On July 18, 2012, Theralase announced that it has selected bladder cancer as the first clinical target in its Novel Photo Dynamic Compound (PDC) research. Theralase now has a clear direction with which to proceed with FDA Clinical Trials. Bladder cancer is the fifth most common cancer in North America being the fourth most common in men and the eighth most common in woman. In North America, it is estimated that there will be over 77,000 new cases and over 15,000 deaths annually.

The Theralase light activated PDC drug has been proven to be superior to any currently approved FDA PDC drug on the market, tested in Theralase’s lab and we are working hard to help eliminate this devastating disease that can dramatically affect so many families.

Theralase plans to aggressively pursue commercialization of our ground-breaking PDC technology through the accelerated FDA regulatory approval process. Theralase feels its technology will prove as effective in bladder cancer preclinical trials that will eventually lead to FDA clinical approval.

Theralase Accelerates Intellectual Property Strategy

On April 13, 2012, Theralase Technologies Inc. announced that it has filed a patent application for a newly developed Photo Dynamic Compound (PDC) to be added to its library of patented Photo Dynamic Compounds. It has been a stated objective to build on these important existing holdings and continue to expand the Intellectual Property footprint of the corporation. This filing represents a significant step in this regard and will specifically target new avenues in the destruction of cancers, bacteria and viruses.

"I had indicated to our shareholders that we would quickly show evidence of our IP strategy," said Roger Dumoulin-White, CEO of Theralase Technologies. "We firmly believe that our patents will be invaluable to Theralase as we continue to execute on our growth plan on the road to commercialization.”

Mr. White added, “Further to our press release of March 28, 2012, I am pleased to say that the mice, with under the skin colon cancer tumours treated with Theralase’s patented anti-cancer PDC technologies have survived and flourished forty-eight days post treatment; the mice continue to be cancer free. Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future.”

Theralase Identifies Leading Anti-Cancer Drug Candidate

On March 14, 2012, Theralase Technologies Inc. announced that it is pursuing FDA Phase 1 approval for its patented Photo Dynamic Compounds (PDCs).

Theralase has successfully identified the leading drug candidate, which will be used for safety and efficacy clinical testing in human cancer patients. In multiple preclinical studies, the leading drug candidate has been selected from Theralase’s library of PDCs and has repeatedly demonstrated:

• extremely high efficacy, virtually 100% kill rate, in various cancer cell lines including brain and colorectal cancers• robust destruction of subcutaneous (under the skin) cancerous tumours in animals• extremely low toxicity • high stability, allowing for a long shelf life

The preclinical results were reviewed by SPIE (The International Society for Optics and Photonics) and were accepted by the Conference Chairs for presentation at the SPIE Photonics Europe conference in Brussels, Belgium.Theralase will validate its extensive data with additional cancer animal models and toxicology analyses. This will provide the results required by the FDA to design a FDA Phase 1 clinical human study to commence in 2013 with scheduled completion in 2014. Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "Achievement of this critical milestone represents irrefutable proof that the Theralase leading drug PDC candidate is effective in the destruction of cancer in live animal models. The treatment was well tolerated by the animals, eliminating their cancer without any adverse effects. The Theralase leading drug candidate has been proven to be superior to any currently approved FDA PDC drug on the market, tested in our lab.”

Theralase Featured on "The Next Biggest Winner" Business TV Series

Theralase was featured on "The Next Biggest Winner", a television series devoted to discovering undervalued companies with the ability to grow significantly in shareholder value and become a big winner as an investment opportunity.

The TV show, "The Next Biggest Winner," which showcases companies with significant growth potential scheduled an in-depth interview with Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. on the iChannel, Tuesday, August 14th at 7:30pm. The iChannel has over 1.3 million affluent Canadian subscribers who look to its business programming for new investment opportunities.

To view the interview, please visit http://www.thenextbiggestwinner.com/theralase-technologies-inc/

Therapeutic Laser Technology (TLT) division

Low Level Laser Therapy (LLLT) is the drug-free, non-invasive and safe (FDA recognised) clinical application of light in the range of 1mW – 500mW to a patient to promote tissue regeneration, reduce inflammation and relieve pain. Theralase technology is the only product on the market that activates all three known cellular pathways (ATP production, iNOS production and Na+ / K+ pump regulation) and provides a depth of penetration of four inches into tissue. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. The White Paper “UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)” may be accessed from the Theralase website and offers independent clinical studies to support the science.

Theralase Establishes Middle East Distribution Network

On May 30, 2012, Theralase Technologies Inc. announced that it had entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria.

MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts including numerous major hospitals, medical clinics and doctors in the region. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.

Theralase Presents at BioFinance 2012 Life Sciences Conference

Roger Dumoulin-White, President and CEO presented the latest corporate information at the BioFinance 2012 conference held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada, which highlights more than 60 diverse life science companies, and the investment opportunities that they present. BioFinance 2012 also featured 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation took place Wednesday, May 30th at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase presented on the strategic direction and recent accomplishments of the company followed by a short Q&A period and one-on-one meetings with investors.

Theralase Closes Equity Financing

On April 13, 2012 Theralase Technologies Inc. stated that it has closed a previously announced private placement (the "Private Placement") of 3,000,000 units (the "Units") at a price of Cdn $0.25 per Unit for gross proceeds of CDN $750,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non-transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the purchaser to purchase one additional common share (a "Warrant Share") in the capital of the Company until April 13, 2013 at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month hold period, expiring August 13, 2012.

The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company's prospects in a number of areas; specifically:

• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network• Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of bacteria and viruses • TLC-1000 and TLC-900 therapeutic medical laser USA sales and marketing expansion• TLC-1000 therapeutic medical laser incorporating TENS (Transcutaneous Electrical Nerve Stimulation)• TLC-2000 therapeutic medical biofeedback laser commercialization

OUTLOOK

Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the TLC-900 controllerless laser series in the Canadian, US and international markets in 2012, supported by new independent scientific research confirming the effectiveness of Theralase’s proprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedback technology for launch in the first quarter of 2013, while researching and developing its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.

The groundwork has been laid for significant growth. Our proven patented technology has no equal and our ability to dramatically scale sales and marketing geographically as well as demographically will allow Theralase significant first mover market advantage. Theralase is currently debt free as it utilizes its profits from the sale of its TLC-1000 and TLC-900 Therapeutic Medical Laser platforms to pay for its future growth in the form of the launch of the TLC-2000 Biofeedback Therapeutic Laser Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer Destruction Technology.

This newsletter contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

For more information, please contact:

Roger Dumoulin-White President & CEO, 416-447-8455 ext. 225 rwhite@theralase.com

Greg BewshDirector of Investor Relations,416-447-8455 ext. 262gbewsh@theralase.com

Kristina HacheyChief Financial Officer

416-447-8455 ext. 224khachey@theralase.com

Dr. Arkady MandelChief Scientific Officer

416-447-8455 ext. 242amandel@theralase.com

UPCOMING WEBINARS

October 23, 2012 Clinical and Business Rewards of Using Laser in PracticeTo register https://www2.gotomeeting.com/register/793806762

November 27, 2012 Current Research in Low Level Laser Therapy

To register https://www2.gotomeeting.com/register/415407642

UPCOMING SEMINARS

Theralase’s Dr. Rhonda Mostyn will be presenting “Modern Science, Classic Healing: Therapeutic Laser Therapy and Chiropractic” at Parker Seminars Toronto on Friday, September 21, 2012 at 11:00 am.

CORPORATE UPDATESTheralase Creates Two Operating Divisions

On August 16, 2012, Theralase announced that it is reorganizing its operations into two separate reportable operating divisions to better service and focus the company's resources for both independent markets. The Therapeutic Laser Technology (TLT) division will be responsible for all aspects of the Company's burgeoning therapeutic laser business, which manufactures products used by healthcare practitioners predominantly for the healing of pain and the Photo Dynamic Therapy (PDT) division, which researches and develops Photo Dynamic Compounds (PDCs) for the destruction of primarily cancer.

It has become evident through the recent successes of both technology platforms that these two operating divisions have unique requirements in terms of financing, staffing, logistics and resource allocation. Our intent is to manage and focus the direction of each division to better execute on their respective strategic objectives. Theralase's mandate is to build both the TLT and PDT divisions into separate $50 million annual recurring revenue models within the next 5 to 7 years.

Photo Dynamic Therapy PDT division

There exists a substantial stream of research on the amount of systemic cytotoxic drugs and physical modalities associated with different types of radiation therapy. Despite its many successes, and in spite of decades of advanced research with highly sophisticated instrumentation, it has not solved many of the basic mysteries of cancer. Worse yet, every gain seems to be more than offset by additional serious problems and contradictions.

Theralase Inc., therefore, offers an innovative Photodynamic therapy (PDT) paradigm and patented approach for the novel anti-cancer technology platform.

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments.

However, contemporary PDT produces mostly superficial effects. Due to a limited light penetration through tissues, the depth of tumor destruction ranges from a few millimeters to up to 1 centimeter. Theralase’s breaking-ground technology offers a complete illumination of this apparent disadvantage. Therefore, Theralase’s technology platform, which offers a number of significant technological improvements and a barrier-breaking innovation, has the potential to become the first PDT integrated into the mainstream of cancer treatment.

Theralase Identifies the First Cancer Target for its Advanced Photo Dynamic Therapy

On July 18, 2012, Theralase announced that it has selected bladder cancer as the first clinical target in its Novel Photo Dynamic Compound (PDC) research. Theralase now has a clear direction with which to proceed with FDA Clinical Trials. Bladder cancer is the fifth most common cancer in North America being the fourth most common in men and the eighth most common in woman. In North America, it is estimated that there will be over 77,000 new cases and over 15,000 deaths annually.

The Theralase light activated PDC drug has been proven to be superior to any currently approved FDA PDC drug on the market, tested in Theralase’s lab and we are working hard to help eliminate this devastating disease that can dramatically affect so many families.

Theralase plans to aggressively pursue commercialization of our ground-breaking PDC technology through the accelerated FDA regulatory approval process. Theralase feels its technology will prove as effective in bladder cancer preclinical trials that will eventually lead to FDA clinical approval.

Theralase Accelerates Intellectual Property Strategy

On April 13, 2012, Theralase Technologies Inc. announced that it has filed a patent application for a newly developed Photo Dynamic Compound (PDC) to be added to its library of patented Photo Dynamic Compounds. It has been a stated objective to build on these important existing holdings and continue to expand the Intellectual Property footprint of the corporation. This filing represents a significant step in this regard and will specifically target new avenues in the destruction of cancers, bacteria and viruses.

"I had indicated to our shareholders that we would quickly show evidence of our IP strategy," said Roger Dumoulin-White, CEO of Theralase Technologies. "We firmly believe that our patents will be invaluable to Theralase as we continue to execute on our growth plan on the road to commercialization.”

Mr. White added, “Further to our press release of March 28, 2012, I am pleased to say that the mice, with under the skin colon cancer tumours treated with Theralase’s patented anti-cancer PDC technologies have survived and flourished forty-eight days post treatment; the mice continue to be cancer free. Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future.”

Theralase Identifies Leading Anti-Cancer Drug Candidate

On March 14, 2012, Theralase Technologies Inc. announced that it is pursuing FDA Phase 1 approval for its patented Photo Dynamic Compounds (PDCs).

Theralase has successfully identified the leading drug candidate, which will be used for safety and efficacy clinical testing in human cancer patients. In multiple preclinical studies, the leading drug candidate has been selected from Theralase’s library of PDCs and has repeatedly demonstrated:

• extremely high efficacy, virtually 100% kill rate, in various cancer cell lines including brain and colorectal cancers• robust destruction of subcutaneous (under the skin) cancerous tumours in animals• extremely low toxicity • high stability, allowing for a long shelf life

The preclinical results were reviewed by SPIE (The International Society for Optics and Photonics) and were accepted by the Conference Chairs for presentation at the SPIE Photonics Europe conference in Brussels, Belgium.Theralase will validate its extensive data with additional cancer animal models and toxicology analyses. This will provide the results required by the FDA to design a FDA Phase 1 clinical human study to commence in 2013 with scheduled completion in 2014. Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "Achievement of this critical milestone represents irrefutable proof that the Theralase leading drug PDC candidate is effective in the destruction of cancer in live animal models. The treatment was well tolerated by the animals, eliminating their cancer without any adverse effects. The Theralase leading drug candidate has been proven to be superior to any currently approved FDA PDC drug on the market, tested in our lab.”

Theralase Featured on "The Next Biggest Winner" Business TV Series

Theralase was featured on "The Next Biggest Winner", a television series devoted to discovering undervalued companies with the ability to grow significantly in shareholder value and become a big winner as an investment opportunity.

The TV show, "The Next Biggest Winner," which showcases companies with significant growth potential scheduled an in-depth interview with Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. on the iChannel, Tuesday, August 14th at 7:30pm. The iChannel has over 1.3 million affluent Canadian subscribers who look to its business programming for new investment opportunities.

To view the interview, please visit http://www.thenextbiggestwinner.com/theralase-technologies-inc/

Therapeutic Laser Technology (TLT) division

Low Level Laser Therapy (LLLT) is the drug-free, non-invasive and safe (FDA recognised) clinical application of light in the range of 1mW – 500mW to a patient to promote tissue regeneration, reduce inflammation and relieve pain. Theralase technology is the only product on the market that activates all three known cellular pathways (ATP production, iNOS production and Na+ / K+ pump regulation) and provides a depth of penetration of four inches into tissue. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. The White Paper “UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)” may be accessed from the Theralase website and offers independent clinical studies to support the science.

Theralase Establishes Middle East Distribution Network

On May 30, 2012, Theralase Technologies Inc. announced that it had entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria.

MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts including numerous major hospitals, medical clinics and doctors in the region. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.

Theralase Presents at BioFinance 2012 Life Sciences Conference

Roger Dumoulin-White, President and CEO presented the latest corporate information at the BioFinance 2012 conference held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada, which highlights more than 60 diverse life science companies, and the investment opportunities that they present. BioFinance 2012 also featured 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation took place Wednesday, May 30th at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase presented on the strategic direction and recent accomplishments of the company followed by a short Q&A period and one-on-one meetings with investors.

Theralase Closes Equity Financing

On April 13, 2012 Theralase Technologies Inc. stated that it has closed a previously announced private placement (the "Private Placement") of 3,000,000 units (the "Units") at a price of Cdn $0.25 per Unit for gross proceeds of CDN $750,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non-transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the purchaser to purchase one additional common share (a "Warrant Share") in the capital of the Company until April 13, 2013 at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month hold period, expiring August 13, 2012.

The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company's prospects in a number of areas; specifically:

• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network• Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of bacteria and viruses • TLC-1000 and TLC-900 therapeutic medical laser USA sales and marketing expansion• TLC-1000 therapeutic medical laser incorporating TENS (Transcutaneous Electrical Nerve Stimulation)• TLC-2000 therapeutic medical biofeedback laser commercialization

OUTLOOK

Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the TLC-900 controllerless laser series in the Canadian, US and international markets in 2012, supported by new independent scientific research confirming the effectiveness of Theralase’s proprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedback technology for launch in the first quarter of 2013, while researching and developing its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.

The groundwork has been laid for significant growth. Our proven patented technology has no equal and our ability to dramatically scale sales and marketing geographically as well as demographically will allow Theralase significant first mover market advantage. Theralase is currently debt free as it utilizes its profits from the sale of its TLC-1000 and TLC-900 Therapeutic Medical Laser platforms to pay for its future growth in the form of the launch of the TLC-2000 Biofeedback Therapeutic Laser Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer Destruction Technology.

This newsletter contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

For more information, please contact:

Roger Dumoulin-White President & CEO, 416-447-8455 ext. 225 rwhite@theralase.com

Greg BewshDirector of Investor Relations,416-447-8455 ext. 262gbewsh@theralase.com

Kristina HacheyChief Financial Officer

416-447-8455 ext. 224khachey@theralase.com

Dr. Arkady MandelChief Scientific Officer

416-447-8455 ext. 242amandel@theralase.com

UPCOMING WEBINARS

October 23, 2012 Clinical and Business Rewards of Using Laser in PracticeTo register https://www2.gotomeeting.com/register/793806762

November 27, 2012 Current Research in Low Level Laser Therapy

To register https://www2.gotomeeting.com/register/415407642

UPCOMING SEMINARS

Theralase’s Dr. Rhonda Mostyn will be presenting “Modern Science, Classic Healing: Therapeutic Laser Therapy and Chiropractic” at Parker Seminars Toronto on Friday, September 21, 2012 at 11:00 am.

CORPORATE UPDATESTheralase Creates Two Operating Divisions

On August 16, 2012, Theralase announced that it is reorganizing its operations into two separate reportable operating divisions to better service and focus the company's resources for both independent markets. The Therapeutic Laser Technology (TLT) division will be responsible for all aspects of the Company's burgeoning therapeutic laser business, which manufactures products used by healthcare practitioners predominantly for the healing of pain and the Photo Dynamic Therapy (PDT) division, which researches and develops Photo Dynamic Compounds (PDCs) for the destruction of primarily cancer.

It has become evident through the recent successes of both technology platforms that these two operating divisions have unique requirements in terms of financing, staffing, logistics and resource allocation. Our intent is to manage and focus the direction of each division to better execute on their respective strategic objectives. Theralase's mandate is to build both the TLT and PDT divisions into separate $50 million annual recurring revenue models within the next 5 to 7 years.

Photo Dynamic Therapy PDT division

There exists a substantial stream of research on the amount of systemic cytotoxic drugs and physical modalities associated with different types of radiation therapy. Despite its many successes, and in spite of decades of advanced research with highly sophisticated instrumentation, it has not solved many of the basic mysteries of cancer. Worse yet, every gain seems to be more than offset by additional serious problems and contradictions.

Theralase Inc., therefore, offers an innovative Photodynamic therapy (PDT) paradigm and patented approach for the novel anti-cancer technology platform.

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments.

However, contemporary PDT produces mostly superficial effects. Due to a limited light penetration through tissues, the depth of tumor destruction ranges from a few millimeters to up to 1 centimeter. Theralase’s breaking-ground technology offers a complete illumination of this apparent disadvantage. Therefore, Theralase’s technology platform, which offers a number of significant technological improvements and a barrier-breaking innovation, has the potential to become the first PDT integrated into the mainstream of cancer treatment.

Theralase Identifies the First Cancer Target for its Advanced Photo Dynamic Therapy

On July 18, 2012, Theralase announced that it has selected bladder cancer as the first clinical target in its Novel Photo Dynamic Compound (PDC) research. Theralase now has a clear direction with which to proceed with FDA Clinical Trials. Bladder cancer is the fifth most common cancer in North America being the fourth most common in men and the eighth most common in woman. In North America, it is estimated that there will be over 77,000 new cases and over 15,000 deaths annually.

The Theralase light activated PDC drug has been proven to be superior to any currently approved FDA PDC drug on the market, tested in Theralase’s lab and we are working hard to help eliminate this devastating disease that can dramatically affect so many families.

Theralase plans to aggressively pursue commercialization of our ground-breaking PDC technology through the accelerated FDA regulatory approval process. Theralase feels its technology will prove as effective in bladder cancer preclinical trials that will eventually lead to FDA clinical approval.

Theralase Accelerates Intellectual Property Strategy

On April 13, 2012, Theralase Technologies Inc. announced that it has filed a patent application for a newly developed Photo Dynamic Compound (PDC) to be added to its library of patented Photo Dynamic Compounds. It has been a stated objective to build on these important existing holdings and continue to expand the Intellectual Property footprint of the corporation. This filing represents a significant step in this regard and will specifically target new avenues in the destruction of cancers, bacteria and viruses.

"I had indicated to our shareholders that we would quickly show evidence of our IP strategy," said Roger Dumoulin-White, CEO of Theralase Technologies. "We firmly believe that our patents will be invaluable to Theralase as we continue to execute on our growth plan on the road to commercialization.”

Mr. White added, “Further to our press release of March 28, 2012, I am pleased to say that the mice, with under the skin colon cancer tumours treated with Theralase’s patented anti-cancer PDC technologies have survived and flourished forty-eight days post treatment; the mice continue to be cancer free. Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future.”

Theralase Identifies Leading Anti-Cancer Drug Candidate

On March 14, 2012, Theralase Technologies Inc. announced that it is pursuing FDA Phase 1 approval for its patented Photo Dynamic Compounds (PDCs).

Theralase has successfully identified the leading drug candidate, which will be used for safety and efficacy clinical testing in human cancer patients. In multiple preclinical studies, the leading drug candidate has been selected from Theralase’s library of PDCs and has repeatedly demonstrated:

• extremely high efficacy, virtually 100% kill rate, in various cancer cell lines including brain and colorectal cancers• robust destruction of subcutaneous (under the skin) cancerous tumours in animals• extremely low toxicity • high stability, allowing for a long shelf life

The preclinical results were reviewed by SPIE (The International Society for Optics and Photonics) and were accepted by the Conference Chairs for presentation at the SPIE Photonics Europe conference in Brussels, Belgium.Theralase will validate its extensive data with additional cancer animal models and toxicology analyses. This will provide the results required by the FDA to design a FDA Phase 1 clinical human study to commence in 2013 with scheduled completion in 2014. Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "Achievement of this critical milestone represents irrefutable proof that the Theralase leading drug PDC candidate is effective in the destruction of cancer in live animal models. The treatment was well tolerated by the animals, eliminating their cancer without any adverse effects. The Theralase leading drug candidate has been proven to be superior to any currently approved FDA PDC drug on the market, tested in our lab.”

Theralase Featured on "The Next Biggest Winner" Business TV Series

Theralase was featured on "The Next Biggest Winner", a television series devoted to discovering undervalued companies with the ability to grow significantly in shareholder value and become a big winner as an investment opportunity.

The TV show, "The Next Biggest Winner," which showcases companies with significant growth potential scheduled an in-depth interview with Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. on the iChannel, Tuesday, August 14th at 7:30pm. The iChannel has over 1.3 million affluent Canadian subscribers who look to its business programming for new investment opportunities.

To view the interview, please visit http://www.thenextbiggestwinner.com/theralase-technologies-inc/

Therapeutic Laser Technology (TLT) division

Low Level Laser Therapy (LLLT) is the drug-free, non-invasive and safe (FDA recognised) clinical application of light in the range of 1mW – 500mW to a patient to promote tissue regeneration, reduce inflammation and relieve pain. Theralase technology is the only product on the market that activates all three known cellular pathways (ATP production, iNOS production and Na+ / K+ pump regulation) and provides a depth of penetration of four inches into tissue. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. The White Paper “UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)” may be accessed from the Theralase website and offers independent clinical studies to support the science.

Theralase Establishes Middle East Distribution Network

On May 30, 2012, Theralase Technologies Inc. announced that it had entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria.

MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts including numerous major hospitals, medical clinics and doctors in the region. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.

Theralase Presents at BioFinance 2012 Life Sciences Conference

Roger Dumoulin-White, President and CEO presented the latest corporate information at the BioFinance 2012 conference held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada, which highlights more than 60 diverse life science companies, and the investment opportunities that they present. BioFinance 2012 also featured 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation took place Wednesday, May 30th at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase presented on the strategic direction and recent accomplishments of the company followed by a short Q&A period and one-on-one meetings with investors.

Theralase Closes Equity Financing

On April 13, 2012 Theralase Technologies Inc. stated that it has closed a previously announced private placement (the "Private Placement") of 3,000,000 units (the "Units") at a price of Cdn $0.25 per Unit for gross proceeds of CDN $750,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non-transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the purchaser to purchase one additional common share (a "Warrant Share") in the capital of the Company until April 13, 2013 at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month hold period, expiring August 13, 2012.

The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company's prospects in a number of areas; specifically:

• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network• Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of bacteria and viruses • TLC-1000 and TLC-900 therapeutic medical laser USA sales and marketing expansion• TLC-1000 therapeutic medical laser incorporating TENS (Transcutaneous Electrical Nerve Stimulation)• TLC-2000 therapeutic medical biofeedback laser commercialization

OUTLOOK

Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the TLC-900 controllerless laser series in the Canadian, US and international markets in 2012, supported by new independent scientific research confirming the effectiveness of Theralase’s proprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedback technology for launch in the first quarter of 2013, while researching and developing its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.

The groundwork has been laid for significant growth. Our proven patented technology has no equal and our ability to dramatically scale sales and marketing geographically as well as demographically will allow Theralase significant first mover market advantage. Theralase is currently debt free as it utilizes its profits from the sale of its TLC-1000 and TLC-900 Therapeutic Medical Laser platforms to pay for its future growth in the form of the launch of the TLC-2000 Biofeedback Therapeutic Laser Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer Destruction Technology.

This newsletter contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

For more information, please contact:

Roger Dumoulin-White President & CEO, 416-447-8455 ext. 225 rwhite@theralase.com

Greg BewshDirector of Investor Relations,416-447-8455 ext. 262gbewsh@theralase.com

Kristina HacheyChief Financial Officer

416-447-8455 ext. 224khachey@theralase.com

Dr. Arkady MandelChief Scientific Officer

416-447-8455 ext. 242amandel@theralase.com

UPCOMING WEBINARS

October 23, 2012 Clinical and Business Rewards of Using Laser in PracticeTo register https://www2.gotomeeting.com/register/793806762

November 27, 2012 Current Research in Low Level Laser Therapy

To register https://www2.gotomeeting.com/register/415407642

UPCOMING SEMINARS

Theralase’s Dr. Rhonda Mostyn will be presenting “Modern Science, Classic Healing: Therapeutic Laser Therapy and Chiropractic” at Parker Seminars Toronto on Friday, September 21, 2012 at 11:00 am.

CORPORATE UPDATESTheralase Creates Two Operating Divisions

On August 16, 2012, Theralase announced that it is reorganizing its operations into two separate reportable operating divisions to better service and focus the company's resources for both independent markets. The Therapeutic Laser Technology (TLT) division will be responsible for all aspects of the Company's burgeoning therapeutic laser business, which manufactures products used by healthcare practitioners predominantly for the healing of pain and the Photo Dynamic Therapy (PDT) division, which researches and develops Photo Dynamic Compounds (PDCs) for the destruction of primarily cancer.

It has become evident through the recent successes of both technology platforms that these two operating divisions have unique requirements in terms of financing, staffing, logistics and resource allocation. Our intent is to manage and focus the direction of each division to better execute on their respective strategic objectives. Theralase's mandate is to build both the TLT and PDT divisions into separate $50 million annual recurring revenue models within the next 5 to 7 years.

Photo Dynamic Therapy PDT division

There exists a substantial stream of research on the amount of systemic cytotoxic drugs and physical modalities associated with different types of radiation therapy. Despite its many successes, and in spite of decades of advanced research with highly sophisticated instrumentation, it has not solved many of the basic mysteries of cancer. Worse yet, every gain seems to be more than offset by additional serious problems and contradictions.

Theralase Inc., therefore, offers an innovative Photodynamic therapy (PDT) paradigm and patented approach for the novel anti-cancer technology platform.

Photodynamic therapy (PDT) is a clinically approved, minimally invasive therapeutic procedure that can exert a selective cytotoxic activity toward malignant cells. The procedure involves administration of a photosensitizing agent followed by irradiation at a wavelength corresponding to an absorbance band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Clinical studies revealed that PDT can be curative, particularly in early stage tumors. It can prolong survival in patients with inoperable cancers and significantly improve quality of life. Minimal normal tissue toxicity, negligible systemic effects, greatly reduced long-term morbidity, lack of intrinsic or acquired resistance mechanisms, and excellent cosmetic as well as organ function-sparing effects of this treatment make it a valuable therapeutic option for combination treatments.

However, contemporary PDT produces mostly superficial effects. Due to a limited light penetration through tissues, the depth of tumor destruction ranges from a few millimeters to up to 1 centimeter. Theralase’s breaking-ground technology offers a complete illumination of this apparent disadvantage. Therefore, Theralase’s technology platform, which offers a number of significant technological improvements and a barrier-breaking innovation, has the potential to become the first PDT integrated into the mainstream of cancer treatment.

Theralase Identifies the First Cancer Target for its Advanced Photo Dynamic Therapy

On July 18, 2012, Theralase announced that it has selected bladder cancer as the first clinical target in its Novel Photo Dynamic Compound (PDC) research. Theralase now has a clear direction with which to proceed with FDA Clinical Trials. Bladder cancer is the fifth most common cancer in North America being the fourth most common in men and the eighth most common in woman. In North America, it is estimated that there will be over 77,000 new cases and over 15,000 deaths annually.

The Theralase light activated PDC drug has been proven to be superior to any currently approved FDA PDC drug on the market, tested in Theralase’s lab and we are working hard to help eliminate this devastating disease that can dramatically affect so many families.

Theralase plans to aggressively pursue commercialization of our ground-breaking PDC technology through the accelerated FDA regulatory approval process. Theralase feels its technology will prove as effective in bladder cancer preclinical trials that will eventually lead to FDA clinical approval.

Theralase Accelerates Intellectual Property Strategy

On April 13, 2012, Theralase Technologies Inc. announced that it has filed a patent application for a newly developed Photo Dynamic Compound (PDC) to be added to its library of patented Photo Dynamic Compounds. It has been a stated objective to build on these important existing holdings and continue to expand the Intellectual Property footprint of the corporation. This filing represents a significant step in this regard and will specifically target new avenues in the destruction of cancers, bacteria and viruses.

"I had indicated to our shareholders that we would quickly show evidence of our IP strategy," said Roger Dumoulin-White, CEO of Theralase Technologies. "We firmly believe that our patents will be invaluable to Theralase as we continue to execute on our growth plan on the road to commercialization.”

Mr. White added, “Further to our press release of March 28, 2012, I am pleased to say that the mice, with under the skin colon cancer tumours treated with Theralase’s patented anti-cancer PDC technologies have survived and flourished forty-eight days post treatment; the mice continue to be cancer free. Based on recent successes in our research, we are confident that Theralase is well positioned to expedite the required steps to initiate human trials in the near future.”

Theralase Identifies Leading Anti-Cancer Drug Candidate

On March 14, 2012, Theralase Technologies Inc. announced that it is pursuing FDA Phase 1 approval for its patented Photo Dynamic Compounds (PDCs).

Theralase has successfully identified the leading drug candidate, which will be used for safety and efficacy clinical testing in human cancer patients. In multiple preclinical studies, the leading drug candidate has been selected from Theralase’s library of PDCs and has repeatedly demonstrated:

• extremely high efficacy, virtually 100% kill rate, in various cancer cell lines including brain and colorectal cancers• robust destruction of subcutaneous (under the skin) cancerous tumours in animals• extremely low toxicity • high stability, allowing for a long shelf life

The preclinical results were reviewed by SPIE (The International Society for Optics and Photonics) and were accepted by the Conference Chairs for presentation at the SPIE Photonics Europe conference in Brussels, Belgium.Theralase will validate its extensive data with additional cancer animal models and toxicology analyses. This will provide the results required by the FDA to design a FDA Phase 1 clinical human study to commence in 2013 with scheduled completion in 2014. Roger Dumoulin-White, President and CEO of Theralase Inc. stated, "Achievement of this critical milestone represents irrefutable proof that the Theralase leading drug PDC candidate is effective in the destruction of cancer in live animal models. The treatment was well tolerated by the animals, eliminating their cancer without any adverse effects. The Theralase leading drug candidate has been proven to be superior to any currently approved FDA PDC drug on the market, tested in our lab.”

Theralase Featured on "The Next Biggest Winner" Business TV Series

Theralase was featured on "The Next Biggest Winner", a television series devoted to discovering undervalued companies with the ability to grow significantly in shareholder value and become a big winner as an investment opportunity.

The TV show, "The Next Biggest Winner," which showcases companies with significant growth potential scheduled an in-depth interview with Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. on the iChannel, Tuesday, August 14th at 7:30pm. The iChannel has over 1.3 million affluent Canadian subscribers who look to its business programming for new investment opportunities.

To view the interview, please visit http://www.thenextbiggestwinner.com/theralase-technologies-inc/

Therapeutic Laser Technology (TLT) division

Low Level Laser Therapy (LLLT) is the drug-free, non-invasive and safe (FDA recognised) clinical application of light in the range of 1mW – 500mW to a patient to promote tissue regeneration, reduce inflammation and relieve pain. Theralase technology is the only product on the market that activates all three known cellular pathways (ATP production, iNOS production and Na+ / K+ pump regulation) and provides a depth of penetration of four inches into tissue. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. The White Paper “UNDERSTANDING THE MECHANISMS OF LOW LEVEL LASER THERAPY (LLLT)” may be accessed from the Theralase website and offers independent clinical studies to support the science.

Theralase Establishes Middle East Distribution Network

On May 30, 2012, Theralase Technologies Inc. announced that it had entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria.

MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts including numerous major hospitals, medical clinics and doctors in the region. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.

Theralase Presents at BioFinance 2012 Life Sciences Conference

Roger Dumoulin-White, President and CEO presented the latest corporate information at the BioFinance 2012 conference held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada, which highlights more than 60 diverse life science companies, and the investment opportunities that they present. BioFinance 2012 also featured 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation took place Wednesday, May 30th at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase presented on the strategic direction and recent accomplishments of the company followed by a short Q&A period and one-on-one meetings with investors.

Theralase Closes Equity Financing

On April 13, 2012 Theralase Technologies Inc. stated that it has closed a previously announced private placement (the "Private Placement") of 3,000,000 units (the "Units") at a price of Cdn $0.25 per Unit for gross proceeds of CDN $750,000.00. Each Unit consists of one common share in the capital of the Company and one-half of one non-transferable common share purchase warrant (a "Warrant"). Each whole Warrant entitles the purchaser to purchase one additional common share (a "Warrant Share") in the capital of the Company until April 13, 2013 at a price of CDN $0.38 per Warrant Share. The securities issued under the Private Placement including any shares issued upon exercise of the Warrants are subject to a four month hold period, expiring August 13, 2012.

The company intends to utilize the proceeds of the offering to provide additional working capital to further develop the Company's prospects in a number of areas; specifically:

• Support of small animal cancer trials at the Ontario Cancer Institute, Princess Margaret Hospital, University Health Network• Research and development of Photo Dynamic Compounds used in conjunction with the patented Theralase laser technology in the destruction of bacteria and viruses • TLC-1000 and TLC-900 therapeutic medical laser USA sales and marketing expansion• TLC-1000 therapeutic medical laser incorporating TENS (Transcutaneous Electrical Nerve Stimulation)• TLC-2000 therapeutic medical biofeedback laser commercialization

OUTLOOK

Theralase will continue to focus on increasing product sales of the TLC-1000 laser technology and the TLC-900 controllerless laser series in the Canadian, US and international markets in 2012, supported by new independent scientific research confirming the effectiveness of Theralase’s proprietary and patented technology. Theralase will commercialize its patented TLC-2000 Biofeedback technology for launch in the first quarter of 2013, while researching and developing its patented TLC-3000 Photo Dynamic Compounds targeting the destruction of cancer, bacteria and viruses.

The groundwork has been laid for significant growth. Our proven patented technology has no equal and our ability to dramatically scale sales and marketing geographically as well as demographically will allow Theralase significant first mover market advantage. Theralase is currently debt free as it utilizes its profits from the sale of its TLC-1000 and TLC-900 Therapeutic Medical Laser platforms to pay for its future growth in the form of the launch of the TLC-2000 Biofeedback Therapeutic Laser Technology and the commercialization of the TLC-3000 Photo Dynamic Compound Cancer Destruction Technology.

This newsletter contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

For more information, please contact:

Roger Dumoulin-White President & CEO, 416-447-8455 ext. 225 rwhite@theralase.com

Greg BewshDirector of Investor Relations,416-447-8455 ext. 262gbewsh@theralase.com

Kristina HacheyChief Financial Officer

416-447-8455 ext. 224khachey@theralase.com

Dr. Arkady MandelChief Scientific Officer

416-447-8455 ext. 242amandel@theralase.com